Zentalis Pharmaceuticals, Inc. (ZNTL)
NASDAQ: ZNTL · Real-Time Price · USD
4.040
+0.250 (6.60%)
At close: Jun 26, 2026, 4:00 PM EDT
4.050
+0.010 (0.25%)
After-hours: Jun 26, 2026, 7:39 PM EDT
Company Description
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States.
It develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types.
The company also develops ZN-c3-001, a phase 1 study that evaluated azenosertib monotherapy in solid tumors; and MAMMOTH (ZN-c3-006) is a Phase 1/2 clinical trial of azenosertib in patients with PARP-inhibitor resistant ovarian cancer.
It has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC. Zentalis Pharmaceuticals, Inc. was incorporated in 2014 and is based in San Diego, California.
Zentalis Pharmaceuticals, Inc.
| Country | United States |
| Founded | 2014 |
| IPO Date | Apr 3, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 106 |
| CEO | Julie Eastland |
Contact Details
Address: 10275 Science Center Dr., Suite 200 San Diego, California 92121 United States | |
| Phone | 858 263 4333 |
| Website | zentalis.com |
Stock Details
| Ticker Symbol | ZNTL |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $18.00 |
| CIK Code | 0001725160 |
| CUSIP Number | 98943L107 |
| ISIN Number | US98943L1070 |
| Employer ID | 82-3607803 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Julie M. Eastland M.B.A. | Chief Executive Officer, President and Director |
| James B. Bucher J.D. | Chief Legal Officer and Corporate Secretary |
| Dr. Ingmar Bruns M.D., Ph.D. | Chief Medical Officer |
| Vincent A. Vultaggio | SVice President of Finance and Principal Accounting Officer |
| Robert J. DiVasto P.E. | Chief Technical Officer |
| Wendy Chang | Chief People Officer |
| Haibo Wang | Chief Business Officer |
| Rajesh Israni | Executive Vice President of Regulatory Affairs and Medical Writing |
| Henry Gu | Senior Vice President and Head of Intellectual Property |
| Sarah Kelly | Senior Vice President of Commercial Strategy |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 18, 2026 | 8-K | Current Report |
| May 27, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| May 27, 2026 | 8-K | Current Report |
| May 21, 2026 | 8-K | Current Report |
| May 12, 2026 | 10-Q | Quarterly Report |
| May 12, 2026 | 8-K | Current Report |
| May 5, 2026 | 8-K | Current Report |
| Apr 30, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 30, 2026 | DEF 14A | Other definitive proxy statements |
| Apr 30, 2026 | ARS | Filing |